In a significant development for the healthcare sector, Jardiance (empagliflozin) has received approval in India form the Central Drugs Standard Control Organization (CDSCO). This approval marks a milestone, allowing nephrologists and cardiologists to utilize Jardiance 10mg tablets for eligible end-stage kidney disease, cardiovascular death, and hospitalization in adults with CKD at risk of progression.
However, it's important to note that Jardiance is not recommended for CKD treatment in patients with polycystic kidney disease, or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.
Gagandeep Singh Bedi, Managing Director of Boehringer Ingelheim India, expressed enthusiasm about the approval, stating, "Chronic kidney disease is an important health issue, and there is a significant unmet need for therapies that slow disease progression and improve outcomes. We are very excited about the approval and the potential for empagliflozin to play an essential role in helping people living with kidney disease and their physicians."
Dr. Shraddha Bhure, Medical Director of Boehringer Ingelheim India, highlighted the gravity of CKD as a major health problem in India, often stemming from common risk factors like diabetes, hypertension, or cardiovascular disease. Patients with CKD progression face increased risks of hospital admissions, cardiac events, kidney failure, and death. Dr. Bhure emphasized that effective management of CKD can lead to substantial improvements in health and economic outcomes, benefiting not only patients and their families but also the society and the country's healthcare system at large.
Comments